Pacemaker syndrome epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Pacemaker syndrome}}
{{Pacemaker syndrome}}
{{CMG}}; {{AE}} {{RT}}
{{CMG}}; {{AE}} {{RT}} [[User:Mohammed Salih|Mohammed Salih, MD.]] [mailto:Mohammed.Salih@stjoeshealth.org]


== Overview ==
== Overview ==

Revision as of 02:33, 27 June 2020

Pacemaker syndrome Microchapters

Home

Overview

Historical Perspective

Pathophysiology

Differentiating Pacemaker syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pacemaker syndrome epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

slides

Images

American Roentgen Ray Society Images of Pacemaker syndrome epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pacemaker syndrome epidemiology and demographics

CDC on Pacemaker syndrome epidemiology and demographics

Pacemaker syndrome epidemiology and demographics in the news

Blogs on Pacemaker syndrome epidemiology and demographics

Directions to Hospitals Treating Pacemaker syndrome

Risk calculators and risk factors for Pacemaker syndrome epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Mohammed Salih, MD. [3]

Overview

Epidemiology

  • The incidence of pacemaker syndrome varies from 2%[1] to 83%.[2] [3]
  • The wide range of reported incidence is likely attributable to two factors, which are, the criteria used to define pacemaker syndrome and the therapy used to resolve that diagnosis.[3]


Incidence

  • The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
  • In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

Prevalence

  • The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
  • In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
  • The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

Case-fatality rate/Mortality rate

  • In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
  • The case-fatality rate/mortality rate of [disease name] is approximately [number range].

Age

  • Patients of all age groups may develop [disease name].
  • The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
  • [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
  • [Chronic disease name] is usually first diagnosed among [age group].
  • [Acute disease name] commonly affects [age group].

Race

  • There is no racial predilection to [disease name].
  • [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

Gender

  • [Disease name] affects men and women equally.
  • [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.

Region

  • The majority of [disease name] cases are reported in [geographical region].
  • [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

Developed Countries

Developing Countries

References

  1. Andersen HR, Thuesen L, Bagger JP, Vesterlund T, Thomsen PE (1994). "Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome". Lancet. 344 (8936): 1523–8. doi:10.1016/S0140-6736(94)90347-6. PMID 7983951. Retrieved 2009-06-19. Unknown parameter |month= ignored (help)
  2. Heldman D, Mulvihill D, Nguyen H; et al. (1990). "True incidence of pacemaker syndrome". Pacing and Clinical Electrophysiology : PACE. 13 (12 Pt 2): 1742–50. doi:10.1111/j.1540-8159.1990.tb06883.x. PMID 1704534. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
  3. 3.0 3.1 Farmer DM, Estes NA, Link MS (2004). "New concepts in pacemaker syndrome". Indian Pacing and Electrophysiology Journal. 4 (4): 195–200. PMC 1502063. PMID 16943933. Retrieved 2009-06-19.

Template:WH Template:WS